ArticleCell reports. Medicine2025
In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence.
Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Review
- Anti-PD-1 single-chain variable fragments in cancer immunotherapy: from molecular engineering to clinical translation.Cancer chemotherapy and pharmacology · 2026Review
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- An ICOSL-armed oncolytic adenovirus activates CD4BMC medicine · 2026Article
- Astragaloside IV-Loaded Polydopamine/Zeolitic Imidazolate Framework-8 Nanoparticles Embedded in Conductive Decellularized Extracellular Matrix-Modified Hydrogels for Wound Healing.Pharmaceutics · 2026Article
- Review
- Functional and mechanistic inactivation of immune hubs orchestrates tumor development and progression in lung adenocarcinoma.Discover oncology · 2026Article
- TIM-3 in AML: a janus-faced orchestrator of immune exhaustion and leukemic self-renewal.Cancer cell international · 2026Review
- Integrating oncolytic adenoviruses into combination cancer therapy: Mechanisms, advances and clinical outlook.Clinical and translational medicine · 2026Review
- When GPVI Goes Rogue: Pathogenesis and Therapeutic Horizons in ITP.Expert reviews in molecular medicine · 2026Review
- The Tumor-Platelet-Immune Interface: Driving Metastasis, Pre-Metastatic Niche Formation and Therapeutic Vulnerabilities.Expert reviews in molecular medicine · 2026Review
- Drug repurposing against viral infections (2020-2025): clinical trials, computational strategies, and therapeutic interventions.Inflammopharmacology · 2026Review
- Targeted Epigenetic Activation ofBiomedicines · 2026Article
- Current Status of Drug Treatment of Cholangiocarcinoma-Updated Progress and Critical Limitations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Mechanistic insights and emerging applications of human metapneumovirus (HMPV) treatment: From molecular design to translational immunity.Folia microbiologica · 2026Review
- Rewriting CAR-T cell fate: CRISPR/Cas gene editing for solid tumor therapy.Frontiers in immunology · 2026Review
- C-reactive protein flare-response predicts the efficacy of PD-1 inhibitors in metastatic gastric cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative tumor recurrence represents a major challenge for patients. Oncolytic virus (OV) therapy has attracted increasing attention in recent years. Here, we construct a supramolecular hydrogel enabling extended release of type V oncolytic adenovirus (adv), with hydrogel stability confirmed experimentally. In situ treatment with the adv-loaded hydrogel (adv@Nap gel) instantly after tumor resection efficiently activates the type I interferon pathway, induces innate and adaptive immunity, controls postoperative tumor recurrence and metastasis, and prolongs mouse survival. We verify the ability of instant in situ treatment with adv@Nap gel to inhibit postoperative tumor recurrence. Notably, oncolytic herpes simplex virus or vaccinia virus loaded in Nap gel can also control postoperative tumor recurrence. Thus, hydrogel-loaded OVs that induce extended immune activation represent a paradigm for sustained antitumor immunotherapy, and in situ sustained immune activation initiated during surgery may represent an important and universal treatment guideline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.